Mangalam Drugs And Organics Limited has informed the Exchange regarding 'Outcome of Board meeting for the Audited Financials for the quarter and year ended 31st March, 2025'.
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mangalam Drugs and Organics reported its audited standalone and consolidated results for Q4 FY25 and the full year ended March 31, 2025, with the auditor (V.S. Somani & Co.) issuing an unmodified opinion. Full-year revenue fell to Rs 31,757.60 lakhs from Rs 36,735.35 lakhs in FY24, a decline of about 13.5%, while Q4 revenue dropped sharply to Rs 7,277.73 lakhs from Rs 10,193.77 lakhs. Despite the topline weakness, the company swung to a net profit of Rs 692.43 lakhs for FY25 from a loss of Rs 904.89 lakhs in FY24, with EPS at Rs 4.37 versus negative Rs 5.72. Operating cash flow improved strongly to Rs 4,275.91 lakhs from Rs 1,216.81 lakhs. The board also appointed Ragini Chokshi & Co. as Secretarial Auditor for FY25, and noted that the merger scheme with Mangalam Laboratories Pvt Ltd and Shri JB Pharma Pvt Ltd is still pending NCLT approval.
Investors may view the FY turnaround to profit and strong cash generation as positives, but the double-digit revenue decline in both the quarter and the year is a concern that could weigh on sentiment. The pending merger scheme and unchanged auditor mean no major governance red flags.